Navigation Links
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
Date:4/15/2008

with day-to-day activities or lessen the quality of life.

About Alcon (NYSE: ACL)

Alcon, Inc. is the world's leading eye care company, with sales of approximately $5.6 billion in 2007. Alcon, which has been dedicated to the ophthalmic industry for 60 years, researches, develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens care solutions and other vision care products that treat diseases, disorders and other conditions of the eye.

Caution Concerning Forward-Looking Statements. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by our forward-looking statements, specifically in regard to the future sales and profits derived from PATANASE(R). These statements reflect the views of our management as of the date of this press release with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward- looking statements. You should read this press release with the understanding that our actual future results may be materially different from what we expect. Except to the extent required under the federal securities laws and the rules an regulations promulgated by the Securities and Exchange Commission, we undertake no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information or future events or circums
'/>"/>

SOURCE Alcon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon
2. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
3. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
4. Researchers Pursuing Nasal Anthrax Vaccine
5. Nasal polyps from analgesics
6. Saline Nasal Wash Helps Kids Fight Colds, Flu
7. Protein Nasal Spray Revives Sleep-Deprived Monkeys
8. Saline Irrigation Eases Chronic Nasal Symptoms
9. New Data Presented at ACAAI Informs on the Safety and Efficacy of Nasacort AQ Nasal Spray in a Trial of Children Aged 2-5 Years Old with Year-Round Allergic Rhinitis
10. U.S. Advisers OK Nasal Spray Flu Vaccine for Young Children
11. As Cold & Flu Season Nears, New Baby Nasal Aspirator Offers Safe and Effective Alternative to FDA-Discouraged Medicines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... , ... Google recently announced that it will be disclosing any incidents involving ... June 8, 2015 article published by Nasdaq , the powerful tech company maintains ... computer-driven cars, which such industry players as Tesla CEO Elon Musk believe may very ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, ... San Bernardino counties, today announced that Dr. Michael Demoratz, PhD, LCSW, CCM is ... a strong proponent of early access to palliative care services for the underserved ...
(Date:7/30/2015)... Philadelphia, PA (PRWEB) , ... July 30, 2015 , ... ... the hospital. In an effort to provide comfort to patients as well as visiting ... an innovative solution: free phone charging stations. , The stations - powered by ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... that the latest issue of Inclusive™ magazine, its multimedia publication focused on implant ... edition of the new issue, Volume 6, Issue 2, as well as past ...
Breaking Medicine News(10 mins):Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 2Health News:New Google Policy on Reporting Driverless Auto Accidents Points Out Growing Complexity of Personal Injury Law in the 21st Century, Says Law Offices of Burg and Brock 3Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 2Health News:24/7 Care At Home Welcomes Michael Demoratz, PhD, LCSW, CCM as New Palliative Care Administrator 3Health News:Hospitals Add Phone Charging Stations as an Amenity for Patients and Visitors 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4
... 2008 - Despite the general success of left ventricular ... patients, implantation of these devices often leads to increased ... and immediately after surgery. A new study published in ... these complications may be significantly reduced by way of ...
... get politicians to act on health care reform is ... surveyed in an opinion poll,commissioned by the Catholic Health ... would be the most effective way to prompt action ... health,care reform would best get the job done. Twenty-two ...
... Fully Understand the Details ... of Their Health Insurance Plan, WESTLAKE VILLAGE, Calif., ... the U.S., yet,contacting plan members regularly and increasing their understanding of,plan ... business and additional sales of services to members,according to the J.D. ...
... ... ... PARIS, April 30 In order to give a,representation of our underlying economic performance, ... EPS (excluding selected items) in U.S. dollars(1) in order to,facilitate comparisons with the majority ...
... the cross hairs of radiation or chemotherapy may be ... jammed, say University of Florida scientists writing in a ... fly cells discovered that slight changes in the protein ... aptly named for their roles in triggering cell death ...
... LONDON, April 30 ,GlaxoSmithKline (NYSE: GSK ) today ... team. In a message to employees, Andrew,Witty, CEO designate, ... take effect on May 22nd when he assumes the ... these changes, Andrew Witty said: "It is,clear that our ...
Cached Medicine News:Health News:Voters Believe They Hold Power in Health Care Reform Debate 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 2Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 3Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 4Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 5Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 6Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 7Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 8Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 9Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 10Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 11Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 12Health News:J.D. Power and Associates Reports: Satisfaction with Health Plans Varies Dramatically From Region To Region, Largely Due to Poor Communication From Insurance Providers 13Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 2Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 3Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 4Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 5Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 6Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 7Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 8Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 9Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 10Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 11Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 12Health News:Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin 13Health News:'Destruct' triggers may be jammed in tumor cells, UF geneticists say 2Health News:GSK Announces Changes to Corporate Executive Team 2Health News:GSK Announces Changes to Corporate Executive Team 3
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: